Johnson & Johnson: Lung Neoplasms trials

The registry lists 13 Lung Neoplasms studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 2Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)TerminatedNCT05299606Not applicableResults posted
• Microwave Ablation in Chinese Patients With Lung TumorsTerminatedNCT04889989Not applicableResults posted
• NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the LungTerminatedNCT03603652Not applicableResults posted
• A Study of Robot-Assisted Bronchoscopy in Chinese Participants With Lung LesionsWithdrawnNCT05426213Not applicable
• Confocal Laser Endomicroscopy Nodule Localization by Robotic BronchoscopyCompletedNCT05231278Not applicable
• Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerApproved for marketingNCT04599712
• A Study of Smoking Cessation Patterns in Participants Undergoing Lung SurgeryCompletedNCT04313361
• Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the LungCompletedNCT04182815
• NEUWAVE Flexible Probe Study #2WithdrawnNCT03713099Not applicable
• A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaCompletedNCT02699606Phase 2
• Powered Echelon Device in VATS SurgeryCompletedNCT01808430
• Fentanyl Matrix in Lung Cancer PainCompletedNCT01060137Phase 4
• A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsCompletedNCT00841191Phase 1/2